NASDAQ:CPRX - Catalyst Pharmaceuticals Stock Price Target and Predictions

Target and Analyst Ratings
Price Target History
Upgrades and Downgrades
About
FAQ

Consensus Rating: Buy
Consensus Price Target: $7.88
Forecasted Upside: 35.54 %
Number of Analysts: 3
Breakdown:
0 Sell Ratings
0 Hold Ratings
3 Buy Ratings
0 Strong Buy Ratings

^$5.81 As of 06/21/2021 04:03 PM ET

▲ +0.08 (1.40%)

1 month | 3 months | 12 months

Get New Catalyst Pharmaceuticals Analyst Ratings Delivered To Your Inbox

Sign-up to receive the latest news and ratings for CPRX and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for CPRX

^$7.88

▲ +35.54% Upside Potential

This price target is based on 3 analysts offering 12 month price targets for Catalyst Pharmaceuticals in the last 3 months. The average price target is $7.88, with a high forecast of $11.00 and a low forecast of $5.50. The average price target represents a 35.54% upside from the last price of $5.81.

Read Analyst Price Chart Description

Current Consensus is Buy

The current consensus among 3 investment analysts is to buy stock in Catalyst Pharmaceuticals. This Buy consensus rating has held steady for over two years.

Past Monthly Recommendations

Move your mouse over past months for details

0 strong buy ratings
4 buy ratings
0 hold ratings
0 sell ratings

Ratings as of

12/29/2019

0 strong buy ratings
4 buy ratings
0 hold ratings
0 sell ratings

Ratings as of

3/28/2020

0 strong buy ratings
4 buy ratings
0 hold ratings
0 sell ratings

Ratings as of

6/26/2020

0 strong buy ratings
6 buy ratings
0 hold ratings
0 sell ratings

Ratings as of

9/24/2020

0 strong buy ratings
6 buy ratings
0 hold ratings
0 sell ratings

Ratings as of

12/23/2020

0 strong buy ratings
4 buy ratings
0 hold ratings
0 sell ratings

Ratings as of

3/23/2021

0 strong buy ratings
3 buy ratings
0 hold ratings
0 sell ratings

Ratings as of

5/22/2021

0 strong buy ratings
3 buy ratings
0 hold ratings
0 sell ratings

Ratings as of

6/21/2021

Latest Recommendations

Show Most Recent Rating from Each Ratings Firm Show All Ratings

Date	Brokerage	Action	Rating	Price Target	Impact on Share Price
5/12/2021	Cantor Fitzgerald	Boost Price Target		$8.00 ➝ $11.00	Medium
3/18/2021	Roth Capital	Boost Price Target	Buy	$6.50 ➝ $7.00	Medium
11/10/2020	Piper Sandler	Lower Price Target	Overweight	$6.00 ➝ $5.50	Low
8/11/2020	Roth Capital	Reiterated Rating	Buy		Medium
8/11/2020	Piper Sandler	Lower Price Target		$7.00 ➝ $6.00	Low
8/4/2020	Oppenheimer	Reiterated Rating	Buy	$8.00	Low
5/13/2020	SunTrust Banks	Lower Price Target	Buy	$11.00 ➝ $10.00	High
2/14/2020	Cantor Fitzgerald	Boost Price Target	Overweight	$11.00 ➝ $12.00	High
12/23/2019	HC Wainwright	Reiterated Rating	Buy	$9.00	Medium
11/13/2019	Piper Jaffray Companies	Lower Price Target		$8.00 ➝ $7.00	High
10/31/2019	HC Wainwright	Reiterated Rating	Buy	$9.00	High
10/9/2019	Piper Jaffray Companies	Set Price Target	Buy	$8.00	N/A
8/8/2019	Cantor Fitzgerald	Boost Price Target		$10.00 ➝ $12.00	Low
8/8/2019	SunTrust Banks	Reiterated Rating	Buy	$9.00 ➝ $11.00	High
5/14/2019	HC Wainwright	Set Price Target	Buy	$9.00	High
5/7/2019	Cantor Fitzgerald	Reiterated Rating	Buy	$10.00	High
3/19/2019	Cantor Fitzgerald	Reiterated Rating	Buy	$10.00	Low
12/14/2018	HC Wainwright	Reiterated Rating	Buy		High
12/13/2018	Cantor Fitzgerald	Set Price Target	Buy	$9.00	High
12/13/2018	Piper Jaffray Companies	Boost Price Target	Overweight ➝ Overweight	$5.00 ➝ $7.50	Low
11/29/2018	Oppenheimer	Set Price Target	Buy	$6.00	Low
11/28/2018	Cantor Fitzgerald	Set Price Target	Buy	$8.00	High
11/9/2018	HC Wainwright	Reiterated Rating	Buy	$6.00	High
11/8/2018	Oppenheimer	Set Price Target	Buy	$6.00	High
11/8/2018	Cantor Fitzgerald	Set Price Target	Buy	$8.00	High
10/26/2018	Cantor Fitzgerald	Set Price Target	Buy	$8.00	Medium
10/16/2018	Oppenheimer	Set Price Target	Buy	$6.00	Low
10/3/2018	Cantor Fitzgerald	Set Price Target	Buy	$8.00	Low
9/21/2018	Cantor Fitzgerald	Initiated Coverage	Overweight		High
9/20/2018	Cantor Fitzgerald	Initiated Coverage	Overweight ➝ Overweight	$8.00	High
9/7/2018	Piper Jaffray Companies	Initiated Coverage	Overweight ➝ Overweight	$5.00	Medium
8/22/2018	HC Wainwright	Set Price Target	Buy	$6.00	High
8/9/2018	Oppenheimer	Set Price Target	Buy	$6.00	High
8/9/2018	HC Wainwright	Reiterated Rating	Buy	$6.00	High
7/12/2018	Oppenheimer	Initiated Coverage	Buy	$6.00	High
3/15/2018	HC Wainwright	Reiterated Rating	Buy	$6.00	High
12/21/2017	HC Wainwright	Reiterated Rating	Buy	$6.00	High
12/1/2017	Piper Jaffray Companies	Set Price Target	Positive ➝ Buy	$8.00	Low
11/29/2017	SunTrust Banks	Reiterated Rating	Buy	$6.00	High
11/10/2017	HC Wainwright	Reiterated Rating	Buy	$6.00	N/A
11/1/2017	Roth Capital	Set Price Target	Buy	$5.00	N/A
10/31/2017	SunTrust Banks	Set Price Target	Buy	$5.00	N/A
9/5/2017	SunTrust Banks	Reiterated Rating	Buy	$5.00	High
8/10/2017	Roth Capital	Set Price Target	Buy	$5.00	Low
8/7/2017	Piper Jaffray Companies	Set Price Target	Buy	$6.00	Low
3/20/2017	Roth Capital	Set Price Target	Buy	$3.00	Low
3/20/2017	HC Wainwright	Reiterated Rating	Buy	$6.00	Low
10/14/2016	Roth Capital	Reiterated Rating	Buy	$2.50	N/A
10/5/2016	Piper Jaffray Companies	Upgrade	Neutral ➝ Overweight	$4.00	N/A

(Data available from 6/21/2016 forward)

Catalyst Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies for people with rare debilitating, chronic neuromuscular, and neurological diseases in the United States. It offers Firdapse, a proprietary form of amifampridine phosphate for the treatment of patients with lambert-eaton myasthenic syndrome (LEMS) and myasthenia gravis; and Ruzurgi for the treatment of pediatric LEMS patients. The company also develops Firdapse for the treatment of anti-MuSK antibody positive myasthenia gravis, and spinal muscular atrophy type 3. It has license agreements with BioMarin Pharmaceutical Inc.; and collaboration and license agreement with Endo Ventures Limited for the development and commercialization of generic Sabril tablets. The company was formerly known as Catalyst Pharmaceutical Partners, Inc. and changed its name to Catalyst Pharmaceuticals, Inc. in May 2015. Catalyst Pharmaceuticals, Inc. was founded in 2002 and is based in Coral Gables, Florida.

Today's Range

Now: $5.81

$5.69

$5.81

50 Day Range

MA: $5.14

$4.29

$5.81

52 Week Range

Now: $5.81

$2.88

$5.90

Volume

21,204 shs

Average Volume

1,551,026 shs

Market Capitalization

$600.54 million

P/E Ratio

8.54

Dividend Yield

N/A

Beta

1.3

Frequently Asked Questions

What sell-side analysts currently cover shares of Catalyst Pharmaceuticals?

The following sell-side analysts have issued stock ratings on Catalyst Pharmaceuticals in the last twelve months: Cantor Fitzgerald, Oppenheimer Holdings Inc., Piper Sandler, Roth Capital, and TheStreet.
View the latest analyst ratings for CPRX.

What is the current price target for Catalyst Pharmaceuticals?

4 Wall Street analysts have set twelve-month price targets for Catalyst Pharmaceuticals in the last year. Their average twelve-month price target is $7.88, suggesting a possible upside of 35.5%. Cantor Fitzgerald has the highest price target set, predicting CPRX will reach $11.00 in the next twelve months. Piper Sandler has the lowest price target set, forecasting a price of $5.50 for Catalyst Pharmaceuticals in the next year.
View the latest price targets for CPRX.

What is the current consensus analyst rating for Catalyst Pharmaceuticals?

Catalyst Pharmaceuticals currently has 3 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Buy." A "buy" rating indicates that analysts believe CPRX will outperform the market and that investors should add to their positions of Catalyst Pharmaceuticals.
View the latest ratings for CPRX.

What other companies compete with Catalyst Pharmaceuticals?

Other companies that are similar to Catalyst Pharmaceuticals include Morphic, Global Blood Therapeutics, Prothena, Centessa Pharmaceuticals, Nuvation Bio, Revance Therapeutics, Deciphera Pharmaceuticals, Xencor, Organogenesis, Ligand Pharmaceuticals, Zentalis Pharmaceuticals, Seres Therapeutics, Amarin, Atea Pharmaceuticals and Myovant Sciences.

How do I contact Catalyst Pharmaceuticals' investor relations team?

Catalyst Pharmaceuticals' physical mailing address is 355 ALHAMBRA CIRCLE SUITE 1250, CORAL GABLES FL, 33134. The biopharmaceutical company's listed phone number is 305-420-3200 and its investor relations email address is [email protected] The official website for Catalyst Pharmaceuticals is www.catalystpharma.com.